PONTE VEDRA, Fla. — November 7, 2025 — Leads & Copy — Treace Medical Concepts, Inc. (NasdaqGS: TMCI) will participate in two upcoming investor conferences, according to a press release issued today. The company aims to advance the standard of care for the surgical management of bunions and related midfoot deformities.
Treace will participate in the UBS Global Healthcare Conference on Monday, November 10, 2025, with a fireside chat scheduled for 11:45 a.m. ET. The company will also attend the Stifel 2025 Healthcare Conference on Tuesday, November 11, 2025.
A live webcast and replay of the fireside chat will be available on the company’s investor relations website.
Treace Medical Concepts, Inc. is focused on advancing the standard of surgical care for bunion and related midfoot deformities. Its flagship product is the Lapiplasty® 3D Bunion Correction® System, which addresses the root cause of bunions through surgical correction of the deformity and stabilization of the unstable joint.
The company estimates that approximately 65 million Americans are affected by bunions, with 1.1 million considered surgical candidates annually. Treace has also introduced the Adductoplasty® Midfoot Correction System, the SpeedMTP™ Rapid Compression Implant, the Nanoplasty™ 3D Minimally Invasive Bunion Correction System, and the Percuplasty™ Percutaneous 3D Bunion Correction System to address a range of bunion types and surgical needs. Treace continues to expand its offerings with the SpeedPlate® Rapid Compression Implants.
Treace Medical Concepts encourages investors to consult the “Investor Relations” section of its website for important information.
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940
Philip Trip Taylor
Gilmartin Group
IR@treace.net
Source: Treace Medical Concepts
